Cemp has bounced back fast during each bio sell off. I expect the same now. Especially with big news coming with in a few weeks. Big block buys will come in if it hits 19 anytime in the next week or so.
The fact that there is a sector that can be so heavily shorted and so easily manipulated really erks me. All they have to do is put huge money on IBB short to easily tank the sector. The short funds are feeling heavy pain of late and the long funds were happy to take their big profits.These ETF's should be banned.
Cemp has not pulled back in the last 3 bio corrections and it won't here either. 11% of the float are short and trapped. When the trial news is public I expect a huge gain. Im sure a New short fund will start a short position expecting the offering to go in to affect. Their gain will be small and fleeting as Cemp will be on every analysts top 5 takeover bio list. Cemp will hold its gains until it is bought out. Cemp will be be bought on every dip. Happy holidays to all Cemp longs.
We believe solithromycin has over $2B in global peak sales potential.” LOL. I know I heard that somewhere else as well……...
If TTPH can be $40 PPS then CEMP could be $50.
I Love Prabhavathi . She basically said, I have a blockbuster, don't even call me unless its a HUGE number. The 10% short? I could never understand that. I think the short funds just shorted everything thinking the IBB was way over bought. Idiots.
Lets say Cemp are good stewards of Soli and don't over prescribe and sales are only 1.5 billion. Sale of company at 4x earnings would fetch appx. $75 a share. You know doctors will prescribe Soli for every little infecttion as it will be the strongest yet safest Macrolide for community available. Cemp may see 3 billion or more in sales. $19 is so cheap its silly.
End of year profit taking. Funds locking gains on the sweet bio run. Cant blame them. Cemp won't go down much. Cheers
Never fight the tape. Cemp is in the " don't short " phase at this point. Undervalued billion dollar drug company nearing NDA. The typical " short phase 1 data after news" does not apply here. Its the opposite actually as the high short position is scrambling to cover.
1 billion peak seems very low. Z-Pac would be in the mulit billions and Soli is more powerful with much moremore indications. The analyst is probably leaving themselves room for upgrades or not including all indications. Im positive we see higher numbers across the board as children,pregnancy etc are approved
" Please feel free to visit us in North Carolina". I love it !!!!! You never hear that from CEO's. Trustworthy,highly experienced bringing antibiotics to market, just a great person. Thank you Prabha.
This statement adds more value to the PPS than a statement that they trying to sell IMHO. They know they have a powerhouse. But…….a huge offer worthy of their intention is whats hidden in the words obviously.
Understatement of the decade. Oral Take home to partner treatment is HUGE. Cap,non complicated gonorrhea, children, pregnancy, body friendly, IV also. 3 billion drug on sale at $19. WOW.
Infectious bugs are getting stronger and more resistant to drugs. Because of that, a British government-commissioned review released Thursday says these "superbugs" could lead to more than 10 million deaths and a $100 trillion global economic impact by 2050.
The Review on Antimicrobial Resistance states about 700,000 people die from antimicrobial resistant bugs each year right now, but that could grow to 10 million - more than the number of people who die from cancer - if action isn't taken.
The study started in July and was lead by Jim O'Neill, a former Goldman Sachs chief economist. O'Neill was selected by United Kingdom Prime Minister David Cameron.
The review looked at three bacteria already showing concerning levels of resistance - Klebsiella pneumonia, E. coli and Staphylococcus aureus - and three public health issues in HIV, tuberculosis and malaria for which resistance is already a concern.